Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tes Pharma S R L currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diverse spread of intellectual property review even at this small scale. Such a distribution suggests that the company's legal challenges are not concentrated under a single individual or specific administrative group, requiring a strategy that addresses multiple perspectives within the patent office.
The workload is distributed such that no single examiner dominates the current prosecution landscape for the portfolio. The busiest examiner identified is RODRIGUEZ, RAYNA B, who is currently managing 1 busiest examiner pending office action. Because this examiner is responsible for 1 of the 2 total actions, the company must coordinate its responses across different reviewers simultaneously. This balanced ratio between the busiest examiner's load and the total number of examiners indicates an even distribution of pending matters across the assigned personnel.
Navigating 2 distinct art units implies that the subject matter of the 2 pending office actions may span different specialized sub-sectors within the broader Biotechnology & Pharmaceuticals field. Practitioners should note that with 2 distinct examiners involved, the prosecution style and requirements may vary between the individual cases. The presence of RODRIGUEZ, RAYNA B as the busiest examiner with 1 busiest examiner pending action highlights the individualized nature of the current patent hurdles facing Tes Pharma S R L.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17184431 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | SHTERENGARTS, SAMANTHA L | 28d |
| 18201674 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | RODRIGUEZ, RAYNA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18201674 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18201674 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Final Rejection | — | Pending | May 24, 2023 |
| 17184431 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | SHTERENGARTS, SAMANTHA L | 1623 | §102§112 | Final Rejection | 28d | Pending | Feb 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial